Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to -$174702.0.

  • Dare Bioscience's Cash from Investing Activities fell 16187.97% to -$174702.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$741486.0, marking a year-over-year decrease of 2007.33%. This contributed to the annual value of -$573046.0 for FY2024, which is 895.79% up from last year.
  • Dare Bioscience's Cash from Investing Activities amounted to -$174702.0 in Q3 2025, which was down 16187.97% from $153396.0 recorded in Q2 2025.
  • Dare Bioscience's Cash from Investing Activities' 5-year high stood at $282325.0 during Q3 2024, with a 5-year trough of -$607331.0 in Q4 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$18311.5 (2021), whereas its average is -$104193.3.
  • In the last 5 years, Dare Bioscience's Cash from Investing Activities crashed by 2241876.16% in 2023 and then surged by 137754.65% in 2024.
  • Dare Bioscience's Cash from Investing Activities (Quarter) stood at -$14524.0 in 2021, then skyrocketed by 81.43% to -$2697.0 in 2022, then tumbled by 22418.76% to -$607331.0 in 2023, then grew by 7.32% to -$562849.0 in 2024, then soared by 68.96% to -$174702.0 in 2025.
  • Its Cash from Investing Activities was -$174702.0 in Q3 2025, compared to $153396.0 in Q2 2025 and -$157331.0 in Q1 2025.